Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Xalkori (crizotinib) [legacy through FY23] by Year
Xalkori (crizotinib) [legacy through FY23] ($M) ($M)
Pfizer Xalkori (crizotinib) [legacy through FY23]: $374M in FY2023, down 19.6% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2023
374
Period ended Dec 31, 2023
Change on a year earlier
-19.6%
465 in FY2022
History
7 years
Since FY2017
Sources
5
Documents cited below
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-22) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Xalkori (crizotinib) [legacy through FY23] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 374 | -19.6% | Form 10-K (filed 2024-02-22) ↗ |
| FY2022 | Dec 31, 2022 | 465 | -5.7% | Form 10-K (filed 2024-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 493 | -9.4% | Form 10-K (filed 2024-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 544 | +2.6% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 530 | +1.1% | Form 10-K (filed 2022-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 524 | -11.8% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 594 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Xalkori (crizotinib) [legacy through FY23] ($M), annual FY2017–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/xalkori-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.